Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
MarketBeat

FORGOTTEN HISTORY: Disc medicine eyes mid 2026 bitopertin approval as epp trial demand surges - The Untold Story

Disc Medicine (NASDAQ:IRON) Chief Executive Officer John Quisel said patient demand for the company’s bitopertin program in erythropoietic protoporphyria, or EPP, remains strong after the company enrolled 183 patients in the APOLLO confirmatory study, above its original target of 150.

Speaking at an H.C. Wainwright event hosted by Senior Analyst Doug Tsao, Quisel said the study’s enrollment pace reflected “tremendous demand and enthusiasm” in both the United States and Europe. He said U.S. enrollment was stopped earlier than expected as the company pursued an accelerated approval pathway, while European sites opened in November and quickly contributed enough patients to reach the 150-patient target by midwinter.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.